ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    291-011
Previous Study | Return to List | Next Study

Brentuximab Vedotin (Recombinant) for IV Infusion - Special Drug Use Surveillance (All-case Surveillance) "Relapsed or Refractory CD30+ Hodgkin's Lymphoma or Anaplastic Large Cell Lymphoma"

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02139592
Recruitment Status : Completed
First Posted : May 15, 2014
Last Update Posted : July 7, 2017
Sponsor:
Information provided by (Responsible Party):
Takeda

Results Submitted - Not Posted on ClinicalTrials.gov
Results information has been submitted to ClinicalTrials.gov by the sponsor or investigator, but is not yet publicly available (or "posted") on ClinicalTrials.gov. The submitted information may not be available if it is pending Quality Control (QC) Review by the National Library of Medicine (NLM) or if issues identified during QC review are being addressed or corrected by the sponsor or investigator. NLM's limited QC review assesses for apparent errors, deficiencies, or inconsistencies. NLM staff do not verify the scientific validity or relevance of the submitted information.
  Recruitment Status : Completed
  Actual Primary Completion Date : June 30, 2017
  Actual Study Completion Date : June 30, 2017

Submission Cycle Results Submitted to ClinicalTrials.gov Results Returned after Quality Control Review
1 June 25, 2018